Panadol 500mg production begins at Jamshoro manufacturing facility

Haleon Pakistan Limited has commenced local production of Panadol 500mg tablets at its manufacturing facility in Jamshoro, marking a significant expansion of the company’s in-house production capabilities. The development was disclosed through a filing submitted to the Pakistan Stock Exchange on October 30.

The start of production follows an investment that the company announced on October 13, 2023. That investment was intended to introduce modern manufacturing technology, expand the Jamshoro plant’s capacity and enable the facility to produce products from the Panadol base portfolio within Pakistan.

Tablets manufactured at the Jamshoro plant will look slightly different from the existing version available in the market. Instead of the familiar “Panadol” text engraved on the tablet, the locally produced medicine will feature a beacon-shaped engraving. The manufacturer stressed that this is solely a design change and does not alter the medicine’s stated quality or efficacy.

The new marking will therefore be an important visual detail for consumers, pharmacists and healthcare providers as the locally manufactured stock enters circulation. Buyers may encounter tablets with the beacon engraving as older inventory bearing the previous text marking is gradually replaced or sold alongside the new production batches.

Bringing production into the company’s own Jamshoro facility is expected to strengthen operational control over manufacturing and increase domestic capacity for a widely used medicine. The company said the move would support more reliable availability of its products for consumers across Pakistan, although it did not disclose the plant’s new production volume or provide a rollout timetable for individual markets.

Local manufacturing can reduce reliance on finished imported supplies and give a producer greater control over production planning, inventory and distribution. The practical benefit will depend on whether the expanded capacity translates into consistent supplies across pharmacies, particularly during periods of unusually high demand.

The announcement represents the implementation of a manufacturing plan first made public three years earlier rather than merely a proposed investment. With commercial production now underway, attention will turn to the distribution of the newly engraved tablets and the effect of the additional domestic capacity on product availability.

No change in dosage, formulation or recommended use was announced as part of the manufacturing transition. Consumers should continue to follow the packaging instructions and professional medical advice, while recognising that the beacon engraving identifies the newly produced tablets from the Jamshoro facility.